<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00210028</url>
  </required_header>
  <id_info>
    <org_study_id>03 SEIN 04</org_study_id>
    <nct_id>NCT00210028</nct_id>
  </id_info>
  <brief_title>Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>Open, Single-Arm Phase II Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer Expressing the Estrogen and/or Progesterone Receptor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the objective response rate when ZARNESTRA is added&#xD;
      to treatment with tamoxifen&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2003</start_date>
  <completion_date>August 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the objective response rate when ZARNESTRA is added to administration of tamoxifen in patients suffering from metastatic or advanced inoperable breast cancer, who are progressing on tamoxifen treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the clinical benefit (response + stable disease at 6 months)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of the combination ZARNESTRA and tamoxifen</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate a possible pharmacokinetic interaction between ZARNESTRA and tamoxifen</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the biological predictive and prognostic factors of a response</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zarnestra</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven, metastatic or locally advanced inoperable breast cancer&#xD;
&#xD;
          -  Tumor considered potentially hormone-sensitive, i.e. presence by IHC of hormone&#xD;
             receptors for estrogens (ER+ for more than 10% of cells) and/or progesterone (Pg+ for&#xD;
             more than 10% of cells) or both. This expression may have been detected on the primary&#xD;
             tumor or at a metastatic site. The method used will be reassessed by IHC if it&#xD;
             involves a radioligand technique whenever it is possible to obtain histological&#xD;
             material.&#xD;
&#xD;
          -  Progressing on treatment with tamoxifen, given either as adjuvant treatment or for&#xD;
             advanced/metastatic breast cancer. Any previous treatment with a steroidal or&#xD;
             nonsteroidal antiaromatase in a neo-adjuvant, adjuvant or metastatic situation is&#xD;
             permitted. Likewise, any previous treatment with chemotherapy and/or herceptin in a&#xD;
             nonmetastatic situation is permitted.&#xD;
&#xD;
          -  Post-menopausal patients&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  At least one measurable lesion according to the Response Evaluation Criteria for Solid&#xD;
             Tumors (RECIST) criteria; for patients who only have bone metastases, an evaluable&#xD;
             non-irradiated lytic lesion is required&#xD;
&#xD;
          -  Performance Status (WHO): PS ≤ 2 (Appendix 1).&#xD;
&#xD;
          -  Laboratory tests in accordance with the following criteria:&#xD;
&#xD;
        Neutrophils ≥ 2x109/l,Platelets ≥ 100x109/l,Hemoglobin ≥ 10 g/dl, ASAT, ALAT ≤ 2.5 N , or &lt;&#xD;
        5 N when liver metastasis,bilirubin ≤ 1.5 N creatinin ≤ 1.5 N&#xD;
&#xD;
          -  Signed, written consent before any study-related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Men&#xD;
&#xD;
          -  Pre-menopausal patients who are not receiving concurrent LHRH agonist therapy&#xD;
&#xD;
          -  ER- and PR-negative patients&#xD;
&#xD;
          -  Contraindication to antiestrogens (thromboembolic risk) or ZARNESTRA&#xD;
&#xD;
          -  Non metastatic tumor susceptible to management by radiotherapeutic and/or surgical&#xD;
             means&#xD;
&#xD;
          -  T4d inflammatory tumor (PEV 2 or 3).&#xD;
&#xD;
          -  Short-term, life-threatening lesions: hepatic invasion &gt; 1/3 of liver volume,&#xD;
             pulmonary lymphangitis, uncontrolled cerebral metastases, carcinomatous meningitis&#xD;
&#xD;
          -  Sensory neuropathy &gt; or = grade 1 (WHO)&#xD;
&#xD;
          -  Previous history of uncontrolled cancers or controlled for less than 5 years, except&#xD;
             basal cell skin cancers and in situ cancers of the cervix.&#xD;
&#xD;
          -  Chronic diseases (somatic or psychiatric) with a poor prognosis&#xD;
&#xD;
          -  subjects with enzyme-inducing anti-convulsants (e.g., phenytoin, phenobarbital,&#xD;
             carbamazepine) : this treatment is not permitted while taking ZARNESTRA&#xD;
&#xD;
          -  Patients who, for family, social, geographic or psychological reasons, could not be&#xD;
             followed up correctly.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henri Roché, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Val d'Aurelle_ Paul Lamarque</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>November 10, 2006</last_update_submitted>
  <last_update_submitted_qc>November 10, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2006</last_update_posted>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Zarnestra</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>estrogen receptor</keyword>
  <keyword>progesterone receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

